Selected Publications

• Brüggenjurgen B, Reinhold T, Brehler R, Laake E, Wiese G, Machate U, et al. Cost-effectiveness of specific subcutaneous immunotherapy in patients with allergic rhinitis and allergic asthma. Annals of Allergy, Asthma & Immunology. 2008;101(3):316-324.
• Brüggenjürgen B, Reinhold T, McBride D, Willich SN. [Atrial fibrillation--epidemiologic, economic and individual burden of disease]. Deutsche Medizinische Wochenschrift. 2010;135(Suppl 2):S21-25.
• DeBucourt M, Busse R, Güttler F, Reinhold T, Vollnberg B, Kentenich M, Hamm B, Teichgräber UK. Process mapping of PTA and stend placement in a university hospital interventional radiology department. Insights Imaging. 2012. [Epub ahead of print].
• Ewest F, Reinhold T, Vloet TD, Wenning V, Bachmann CJ. Durch Jugendliche mit Störungen des Sozialverhaltens ausgelöste Krankenkassenausgaben - Eine gesundheitsökonomische Analyse von Versichertendaten einer gesetzlichen Krankenkasse. Kindheit und Entwicklung 2013; 22(1): 41-47.
• Lindig C, Brüggenjürgen B, Willich SN, Reinhold T. Die Kosten des Schlaganfalls – eine Längsschnittanalyse. Pharmacoeconomics - German research articles 2010; 8(2):97-107.
• Lock JF, Reinhold T, Malinowski M, Pratschke J, Neuhaus P, Stockmann M. The costs of postoperative liver failure and the economic impact of liver function capacity after extended liver resection-a single-center experience. Langenbeck's Archives of Surgery. 2009 Nov;394(6):1047-1056.
• Müller-Riemenschneider F, Reinhold T, Berghofer A, Willich SN. Health-economic burden of obesity in Europe. European Journal of Epidemiology. 2008;23(8):499-509.
• Müller-Riemenschneider F, Reinhold T, Willich SN. [Second-generation DES: New, but also cost-effective?] Herz. 2011;36(3):254-261.
• Müller-Riemenschneider F, Reinhold T, Willich SN. Cost-effectiveness of interventions promoting physical activity. British Journal of Sports Medicine. 2009;43(1):70-76.
• Norman K, Pirlich M, Smoliner C, Kilbert A, Schulzke JD, Ockenga J, Lochs H, Reinhold T. Cost-effectiveness of a 3-months intervention with oral nutritional supplements in disease related malnutrition: A randomized controlled Pilot study. European Journal of Clinical Nutrition. 2011;65(6):735-742.
• Pisa G, Reinhold T, Obi-Tabot E, Bodoria M, Brüggenjürgen B. Critical Limb Ischemia and Its Impact on Patient Health Preferences and Quality of Life—An International Study. Int J Angiol 2012; 21(03): 139-146.
• Reinhold T*, Thierfelder K*, Müller-Riemenschneider F, Willich SN. [Health Economic Effects after DRG-Implementation - A systematic Overview]. Gesundheitswesen. 2009;71:306-312. (*contributed equally)
• Reinhold T, Andersohn F, Hessel F, Brüggenjürgen B, Willich SN. Die Nutzung von Routinedaten der gesetzlichen Krankenkassen (GKV) zur Beantwortung gesundheitsökonomischer Fragenstellungen – eine Potentialanalyse. Gesundheitsökonomie und Qualitätsmanagement. 2011;16:153-159.
• Reinhold T, Berghoefer A, Willich SN. [Is the Determination of Biomarkers Worth Its Price? Review of the Literature Taking Brain Natriuretic Peptides (BNP) as an Example.] Herz. 2010;35:1-10.
• Reinhold T, Brüggenjürgen B, Schlander M, Rosenfeld S, Hessel F, Willich SN. Economic Analysis Based on Multinational Studies – Methods for Adapting Findings to National Contexts. Journal of Public Health. 2010;18(4):327-335.
• Reinhold T, Lindig C, Willich SN, Brüggenjürgen B. [Patient characteristics in German allergological practices – a nationwide survey.] Allergologie 2011; 34(5):237-247.
• Reinhold T, Lindig C, Willich SN, Brüggenjürgen B. The costs of atrial fibrillation in patients with cardiovascular comorbidities - a longitudinal analysis of German health insurance data. Europace. 2011 Sep;13(9):1275-1280.
• Reinhold T, Lindig C, Willich SN, Brüggenjürgen B. The costs of myocardial infarction – a longitudinal analysis using data from a large German health insurance company. Journal of Public Health. 2011. 19:579-586.
• Reinhold T, Müller-Riemenschneider F, McBride D, Brüggenjürgen B, Willich SN. [Cardiovascular diseases in the focus of health economics - the example of drug-eluting vascular stents in coronary heart disease.] Bundesgesundheitsblatt. 2012;55:693-699.
• Reinhold T, Müller-Riemenschneider F, Willich SN, Brüggenjürgen B. Economic and human costs of restless legs syndrome. Pharmacoeconomics. 2009;27(4):267-279.
• Reinhold T, Rosenfeld S, Müller-Riemenschneider F, Willich SN, Meinertz T, Kichhof P, Brüggenjürgen B. [Characteristics, resource consumption and costs of patients suffering from Atrial fibrillation in Germany.] Herz. 2012 Aug;37(5):534-42.
• Reinhold T, von Schultzendorf A, Müller-Riemenschneider F. Economic consequences of overweight and obesity in Asia-Pacific. European Journal of Integrated Medicine. 2011;3:3-9.
• Reinhold T, Willich SN, Brüggenjürgen B. Subcutaneous specific immunotherapy: Economic implications from the perspective of statutory health insurance – a population based cost-effectiveness analysis. Allergologie 2012; [Epub ahead of print].
• Ricken R, Wiethoff K, Reinhold T, Schietsch K, Stamm T, Kiermeir J, Neu P, Heinz A, Bauer M, Adli M. Algorithm-guided treatment of depression reduces treatment costs - Results from the randomized controlled German Algorithm Project (GAPII). Journal of Affective Disorders. 2011. 134(1-3):249-56.
• Ultsch B, Siedler A, Rieck T, Reinhold T, Krause G, Wichmann O. Herpes zoster in Germany: Quantifying the burden of disease. BMC Infectious Diseases. 2011;11(1):173.
• Willich SN, Reinhold T. Money Meets Medicine. 2. Jahreskonferenz der Deutschen Gesellschaft für Gesundheitsökonomie. Gesundheitsökonomie und Qualitätsmanagement. 2010;15:108-109.